300294 Stock Overview
Engages in the blood product businesses in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.90 |
| 52 Week High | CN¥41.98 |
| 52 Week Low | CN¥22.91 |
| Beta | 0.40 |
| 1 Month Change | -6.11% |
| 3 Month Change | -13.71% |
| 1 Year Change | 3.96% |
| 3 Year Change | -17.03% |
| 5 Year Change | -4.93% |
| Change since IPO | 235.18% |
Recent News & Updates
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Recent updates
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings
Sep 12Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark
Jun 12China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31Shareholder Returns
| 300294 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.8% | 3.1% | 3.5% |
| 1Y | 4.0% | -17.3% | 10.9% |
Return vs Industry: 300294 exceeded the CN Biotechs industry which returned -17.3% over the past year.
Return vs Market: 300294 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 300294 volatility | |
|---|---|
| 300294 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 300294 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300294's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,444 | Xiaoming Liang | www.china-boya.com |
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible tablets.
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Fundamentals Summary
| 300294 fundamental statistics | |
|---|---|
| Market cap | CN¥14.62b |
| Earnings (TTM) | CN¥186.10m |
| Revenue (TTM) | CN¥1.71b |
78.3x
P/E Ratio8.5x
P/S RatioIs 300294 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300294 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.71b |
| Cost of Revenue | CN¥579.41m |
| Gross Profit | CN¥1.13b |
| Other Expenses | CN¥941.18m |
| Earnings | CN¥186.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 19, 2025
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 66.05% |
| Net Profit Margin | 10.90% |
| Debt/Equity Ratio | 0.03% |
How did 300294 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield125%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 16:45 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Fang Quan | China International Capital Corporation Limited |
| Bing Zhao | China Renaissance Securities |